Ovarian tissue cryopreservation in Malaysia: a case series.

IF 1.1 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Hormone Molecular Biology and Clinical Investigation Pub Date : 2022-12-01 DOI:10.1515/hmbci-2021-0096

Norazilah Mat Jin, Siti Maisarah Ahmad, Ahmad Mohd Faizal, Abdul Kadir Bin Abdul Karim, Muhammad Azrai Abu

{"title":"Ovarian tissue cryopreservation in Malaysia: a case series.","authors":"Norazilah Mat Jin, Siti Maisarah Ahmad, Ahmad Mohd Faizal, Abdul Kadir Bin Abdul Karim, Muhammad Azrai Abu","doi":"10.1515/hmbci-2021-0096","DOIUrl":null,"url":null,"abstract":"Objectives: We aim to discuss the hematological cancer cases that opted for ovarian tissue cryopreservation (OTC) as fertility preservation before the gonadotoxic chemotherapy agent.Case presentation: The ovarian tissue cryopreservation (OTC) was started in August 2020 in our center. Up to now, there were four cases have been performed and included in this report. The ovarian tissue cortex was cryopreserved with cryoprotectant using Kitazato™ (Tokyo, Japan) media and fit in the closed system devices. A total of four post-OTC patients were included. The mean age was 24 years old, whereas the mean serum AMH level was 30.43 pmol/L. Most of them were diagnosed with lymphoma, except one was leukemia. All of them received additional GnRH analog following OTC as a chemoprotective agent before cancer treatment. Currently, they are recovering well and on regular follow-up with the hematological department.Conclusions: Although The OTC is an ultimate option for prepubertal girls, it can be proposed as a good strategy for adult cancer women who could not delay cancer therapy.","PeriodicalId":13224,"journal":{"name":"Hormone Molecular Biology and Clinical Investigation","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone Molecular Biology and Clinical Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/hmbci-2021-0096","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Objectives: We aim to discuss the hematological cancer cases that opted for ovarian tissue cryopreservation (OTC) as fertility preservation before the gonadotoxic chemotherapy agent.

Case presentation: The ovarian tissue cryopreservation (OTC) was started in August 2020 in our center. Up to now, there were four cases have been performed and included in this report. The ovarian tissue cortex was cryopreserved with cryoprotectant using Kitazato™ (Tokyo, Japan) media and fit in the closed system devices. A total of four post-OTC patients were included. The mean age was 24 years old, whereas the mean serum AMH level was 30.43 pmol/L. Most of them were diagnosed with lymphoma, except one was leukemia. All of them received additional GnRH analog following OTC as a chemoprotective agent before cancer treatment. Currently, they are recovering well and on regular follow-up with the hematological department.

Conclusions: Although The OTC is an ultimate option for prepubertal girls, it can be proposed as a good strategy for adult cancer women who could not delay cancer therapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

马来西亚卵巢组织冷冻保存:一个案例系列。

目的:探讨在使用促性腺毒素化疗前选择卵巢组织冷冻保存(OTC)作为生育能力保存的血液病病例。病例介绍:我中心于2020年8月启动卵巢组织冷冻保存(OTC)。到目前为止，已经完成了4例，并纳入了本报告。使用Kitazato™(Tokyo, Japan)培养基用冷冻保护剂冷冻保存卵巢组织皮层，并将其放入封闭系统装置中。共纳入4例otc后患者。平均年龄24岁，血清AMH平均值为30.43 pmol/L。除1例白血病外，大部分患者都被诊断为淋巴瘤。在癌症治疗前，所有患者都在OTC后接受了GnRH类似物作为化学保护剂。目前，他们恢复良好，并定期随访血液科。结论:虽然OTC是青春期前女孩的最终选择，但对于不能延迟癌症治疗的成年癌症妇女来说，它是一个很好的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hormone Molecular Biology and Clinical Investigation BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

2.60

自引率

0.00%

发文量

期刊介绍： Hormone Molecular Biology and Clinical Investigation (HMBCI) is dedicated to the provision of basic data on molecular aspects of hormones in physiology and pathophysiology. The journal covers the treatment of major diseases, such as endocrine cancers (breast, prostate, endometrium, ovary), renal and lymphoid carcinoma, hypertension, cardiovascular systems, osteoporosis, hormone deficiency in menopause and andropause, obesity, diabetes, brain and related diseases, metabolic syndrome, sexual dysfunction, fetal and pregnancy diseases, as well as the treatment of dysfunctions and deficiencies. HMBCI covers new data on the different steps and factors involved in the mechanism of hormone action. It will equally examine the relation of hormones with the immune system and its environment, as well as new developments in hormone measurements. HMBCI is a blind peer reviewed journal and publishes in English: Original articles, Reviews, Mini Reviews, Short Communications, Case Reports, Letters to the Editor and Opinion papers. Ahead-of-print publishing ensures faster processing of fully proof-read, DOI-citable articles.